Karyopharm Therapeutics (KPTI) Announces Top-Line Selinexor Phase 2b Data in Multiple Myeloma

September 6, 2016 7:02 AM
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) reported positive top-line results from its Phase 2b STORM study evaluating the activity of selinexor ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Management Comments Trader Talk Trading Halts

Next Articles